Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07529808 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 164 | BigHat Biosciences, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT06005493 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 392 | AstraZenecaINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 2 | 740 | Daiichi SankyoINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 190 | XYone Therapeutics, IncINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06123338 | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | recruiting | Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07069712 | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | recruiting | Phase 2 | 100 | AstraZenecaINDUSTRY | 11 | Sep 24, 2026 | clinicaltrials |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | recruiting | Phase 2 | 454 | AstraZenecaINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT06253650 | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease(TRINITY) | recruiting | Phase 2 | 46 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07631000 | A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | recruiting | Phase 1 / Phase 2 | 768 | Boehringer IngelheimINDUSTRY | 10 | Sep 16, 2026 | clinicaltrials |
| NCT05438459 | GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites | recruiting | Phase 1 / Phase 2 | 176 | Kyushu UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06730373 | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) | recruiting | Phase 2 | 110 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07000253 | Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma(OMEC-5) | recruiting | Phase 2 | 290 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT03219593 | Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04107077 | Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer | recruiting | Phase 2 | 21 | University of ChicagoOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07294664 | PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer | recruiting | Phase 2 | 78 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07070466 | Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03190941 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | recruiting | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity(STOPGAP II) | recruiting | Phase 2 / Phase 3 | 148 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06826079 | Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer(SNCCTGC) | recruiting | Phase 2 | 86 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07025889 | IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer | recruiting | Phase 1 / Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07757165 | The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy(ESMGC) | recruiting | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma(PLATANUS) | recruiting | Phase 2 | 136 | National Cancer Center, JapanOTHER_GOV | 2 | Aug 5, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT06219941 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | recruiting | Phase 2 | 226 | AstraZenecaINDUSTRY | 14 | Jul 29, 2026 | clinicaltrials |
| NCT07692204 | A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 30 | SanofiINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04840264 | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction | recruiting | Phase 2 | 79 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07689851 | Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06630130 | Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer | recruiting | Phase 2 | 100 | Jeeyun LeeOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
Data updated 15 hours agoSource updated Sep 29, 2026source: clinicaltrials